Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Gilead Presents New HIV Treatment And Cure Research Data
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
Becker's Hospital Review1h
HIV drug could offer yearlong protection with a single shot
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...
BioPharma Dive2h
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.
The American Journal of Managed Care3h
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...
PipelineReview.com3h
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...
PipelineReview.com4h
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...
BioSpace5h
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
STAT5h
SAMHSA employees detail an agency in shambles
The Trump administration has cut around 100 employees, or roughly 10%, of the federal agency that oversees mental and ...
KFF Health News5h
Gilead’s HIV Drug Prevents Infection With One Shot A Year Instead Of Two
The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...
አል ዐይን ኒውስ6h
በሙከራ ላይ የነበሩ የኤችአይቪ ኤድስ መድሃኒቶች ምን ላይ ናቸው?
የሚሊዮን ዜጎችን ህይወት የቀጠፈው ኤችአይቪ ኤድስ በሽታ እስካሁን ፈዋሽ መድሃኒት ያልተገኘለት ሲሆን የዓለም ጤና ድርጅት ለቫይረሱ መድሃኒት ለማግኘት የተለያዩ ጥረቶችን በማድረግ ላይ ነው፡፡ ከአምስት ዓመት በኋላ ማለትም በ2030 የቫይረሱን ወረርሽኝ የማጥፋት እቅድ ያስቀመጠ ሲሆን ለዚህ የሚረዱ የተለያዩ ሙከራዎች ...